GLP-1 Drugs May Pose Disproportionate Risks for EDS Patients
Clinical insights suggest GLP-1 agonists may pose extra risks for Ehlers-Danlos Syndrome patients, as delayed gastric emptying can exacerbate GI connective tissue vulnerabilities.
1 story
Clinical insights suggest GLP-1 agonists may pose extra risks for Ehlers-Danlos Syndrome patients, as delayed gastric emptying can exacerbate GI connective tissue vulnerabilities.